Vontobel Holding Ltd. Acquires 4,109 Shares of Biogen Inc. (NASDAQ:BIIB)

Vontobel Holding Ltd. grew its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 36.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,262 shares of the biotechnology company's stock after acquiring an additional 4,109 shares during the quarter. Vontobel Holding Ltd.'s holdings in Biogen were worth $2,334,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Ashton Thomas Securities LLC bought a new stake in shares of Biogen in the third quarter valued at approximately $33,000. Venturi Wealth Management LLC boosted its position in shares of Biogen by 73.8% in the third quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 93 shares during the period. Itau Unibanco Holding S.A. lifted its position in Biogen by 63.8% in the third quarter. Itau Unibanco Holding S.A. now owns 231 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 90 shares during the period. Golden State Wealth Management LLC bought a new position in Biogen in the fourth quarter worth $41,000. Finally, Quent Capital LLC lifted its position in Biogen by 31.9% in the fourth quarter. Quent Capital LLC now owns 298 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 72 shares during the period. 87.93% of the stock is owned by institutional investors.

Biogen Trading Up 0.3 %

BIIB traded up $0.40 during midday trading on Thursday, reaching $137.08. 2,056,403 shares of the company were exchanged, compared to its average volume of 1,437,673. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. Biogen Inc. has a one year low of $128.51 and a one year high of $238.00. The stock has a market capitalization of $20.07 billion, a P/E ratio of 12.25, a PEG ratio of 1.47 and a beta of -0.08. The stock's 50-day simple moving average is $145.71 and its 200 day simple moving average is $171.46.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. As a group, analysts forecast that Biogen Inc. will post 15.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on BIIB. StockNews.com cut Biogen from a "strong-buy" rating to a "buy" rating in a research report on Saturday, December 28th. Mizuho reduced their target price on Biogen from $251.00 to $207.00 and set an "outperform" rating for the company in a research report on Thursday, November 21st. Stifel Nicolaus cut Biogen from a "buy" rating to a "hold" rating and set a $175.00 target price for the company. in a research report on Monday, December 16th. Sanford C. Bernstein began coverage on Biogen in a research report on Tuesday, February 11th. They issued a "market perform" rating and a $160.00 target price for the company. Finally, Truist Financial reduced their target price on Biogen from $220.00 to $210.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat, Biogen currently has a consensus rating of "Hold" and a consensus price target of $211.85.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.